Executive Director, Global Clinical Development, Amgen
Rachel Wagman is Executive Director in the Bone/Nephrology Therapeutic Area at Amgen. She focuses on phase 3/4 clinical development and provides leadership in cross-functional osteoporosis-related issues, including engagement with worldwide regulatory authorities. She has published in several peer-reviewed journals and given invited presentations throughout the United States on osteoporosis.Wagman received her undergraduate degree from the University of Pennsylvania, medical degree from Jefferson Medical College, completed her internal medicine training at Thomas Jefferson University Hospital, and postdoctoral fellowship in endocrinology at Stanford University School of Medicine. She is board-certified in both internal medicine and endocrinology, gerontology, and metabolism.